Jessica Iegre

Jessica Iegre

Auto-generated profile, based on publicly available information

Jessica Iegre

Yusuf Hamied Department of Chemistry University of Cambridge Lensfield Road Cambridge CB2 1EW UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2020 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
BCBethany M. Cooper
Bethany M. Cooper
JIJessica Iegre
Jessica Iegre
DDDaniel H. O' Donovan
Daniel H. O' Donovan
MHMaria Ölwegård Halvarsson
Maria Ölwegård Halvarsson
DSDavid Spring
David Spring
A tutorial review showcasing how peptide–drug conjugates can offer the versatility needed for a successful drug discovery approach, their problems and future opportunities.

1 July 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Open access
CFClaudia De Fusco
Claudia De Fusco
PBPaul Brear
Paul Brear
JIJessica Iegre
Jessica Iegre
KGKathy Hadje Georgiou
Kathy Hadje Georgiou
HSHannah F. Sore
Hannah F. Sore
DSDavid Spring
David Spring
Recently we reported the discovery of a potent and selective CK2α inhibitor CAM4066. This compound inhibits CK2 activity by exploiting a pocket located outside the ATP binding site (αD pocket). Here we describe in detail the journey that led to the discovery of CAM4066 using the challenging fragment linking strategy. Specifically, we aimed to develop inhibitors by linking a high-affinity fragment anchored in the αD site to a weakly binding warhead fragment occupying the ATP site. Moreover, we describe the remarkable impact that molecular modelling had on the development of this novel chemical tool. The work described herein shows potential for the development of a novel class of CK2 inhibitors.

1 December 2013 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
Tiziano TuccinardiTiziano Tuccinardi
Tiziano Tuccinardi
CGCarlotta Granchi
Carlotta Granchi
JIJessica Iegre
Jessica Iegre
IPIlaria Paterni
Ilaria Paterni
SBSimone Bertini
Simone Bertini
Filippo MinutoloFilippo Minutolo
Filippo Minutolo

7 August 2018 in Advanced Therapeutics
Verified
Journal Article
Closed access
PDF file
JIJessica Iegre
Jessica Iegre
JGJosephine S. Gaynord
Josephine S. Gaynord
NRNaomi Robertson
Naomi Robertson
HSHannah F. Sore
Hannah F. Sore
MHMarko Hyvönen
Marko Hyvönen
DSDavid Spring
David Spring

20 February 2018 in Chemical Science
Verified
Journal Article
Open access
PDF file
JIJessica Iegre
Jessica Iegre
PBPaul Brear
Paul Brear
CFClaudia De Fusco
Claudia De Fusco
MYMasao Yoshida
Masao Yoshida
SMSophie L. Mitchell
Sophie L. Mitchell
DSDavid Spring
David Spring
CK2 is a critical cell cycle regulator that also promotes various anti-apoptotic mechanisms. Development of ATP-non-competitive inhibitors of CK2 is a very attractive strategy considering that the ATP binding site is highly conserved among other kinases. We have previously utilised a pocket outside the active site to develop a novel CK2 inhibitor, CAM4066. Whilst CAM4066 bound to this new pocket it was also interacting with the ATP site: herein, we describe an example of a CK2α inhibitor that binds completely outside the active site. This second generation αD-site binding inhibitor, compound CAM4712 (IC50 = 7 μM, GI50 = 10.0 ± 3.6 μM), has numerous advantages over the previously reported CAM4066, including a reduction in the number of rotatable bonds, the absence of amide groups susceptible to the action of proteases and improved cellular permeability. Unlike with CAM4066, there was no need to facilitate cellular uptake by making a prodrug. Moreover, CAM4712 displayed no drop off between its ability to inhibit the kinase in vitro (IC50) and the ability to inhibit cell proliferation (GI50).

12 April 2019 in Chemical Science
Verified
Journal Article
Open access
PDF file
JIJessica Iegre
Jessica Iegre
PBPaul Brear
Paul Brear
DBDavid J. Baker
David J. Baker
Yaw Sing TanYaw Sing Tan
Yaw Sing Tan
EAEleanor Atkinson
Eleanor Atkinson
DSDavid Spring
David Spring
The discovery of new Protein–Protein Interaction (PPI) modulators is currently limited by the difficulties associated with the design and synthesis of selective small molecule inhibitors. Peptides are a potential solution for disrupting PPIs; however, they typically suffer from poor stability in vivo and limited tissue penetration hampering their wide spread use as new chemical biology tools and potential therapeutics. In this work, a combination of CuAAC chemistry, molecular modelling, X-ray crystallography, and biological validation allowed us to develop highly functionalised peptide PPI inhibitors of the protein CK2. The lead peptide, CAM7117, prevents the formation of the holoenzyme assembly in vitro, slows down proliferation, induces apoptosis in cancer cells and is stable in human serum. CAM7117 could aid the development of novel CK2 inhibitors acting at the interface and help to fully understand the intracellular pathways involving CK2. Importantly, the approach adopted herein could be applied to many PPI targets and has the potential to ease the study of PPIs by efficiently providing access to functionalised peptides.